Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.95 USD
-0.09 (-2.23%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $3.94 -0.01 (-0.25%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FATE 3.95 -0.09(-2.23%)
Will FATE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FATE
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
What's in Store for Biogen (BIIB) This Earnings Season?
Other News for FATE
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fly Intel: After-Hours Movers